
## **Dexian Zheng**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9079871/publications.pdf Version: 2024-02-01



DEVIAN THENC

#	Article	IF	CITATIONS
1	Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy. Molecular Therapy - Oncolytics, 2021, 21, 329-339.	4.4	6
2	A novel anti-DR5 antibody-drug conjugate possesses a high-potential therapeutic efficacy for leukemia and solid tumors. Theranostics, 2019, 9, 5412-5423.	10.0	23
3	GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90. Oncogene, 2018, 37, 4505-4517.	5.9	36
4	A novel humanized antiâ€ŧumor necrosis factorâ€related apoptosisâ€inducing ligandâ€R2 monoclonal antibody induces apoptotic and autophagic cell death. IUBMB Life, 2017, 69, 735-744.	3.4	10
5	The IncRNA SNHG5/miRâ€32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. FASEB Journal, 2017, 31, 893-903.	0.5	158
6	Combination of AAV-TRAIL with miR-221-Zip Therapeutic Strategy Overcomes the Resistance to TRAIL Induced Apoptosis in Liver Cancer. Theranostics, 2017, 7, 3228-3242.	10.0	30
7	Transcriptome Identified IncRNAs Associated with Renal Fibrosis in UUO Rat Model. Frontiers in Physiology, 2017, 8, 658.	2.8	31
8	Mmu-miR-125b overexpression suppresses NO production in activated macrophages by targeting eEF2K and CCNA2. BMC Cancer, 2016, 16, 252.	2.6	19
9	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
10	A double feedback loop mediated by microRNA-23a/27a/24-2 regulates M1 <i>versus</i> M2 macrophage polarization and thus regulates cancer progression. Oncotarget, 2016, 7, 13502-13519.	1.8	103
11	Functions of miR-146a and miR-222 in Tumor-associated Macrophages in Breast Cancer. Scientific Reports, 2015, 5, 18648.	3.3	75
12	RIP1 modulates death receptor mediated apoptosis and autophagy in macrophages. Molecular Oncology, 2015, 9, 806-817.	4.6	22
13	Tumor necrosis factor–related apoptosis-inducing ligand induces the expression of proinflammatory cytokines in macrophages and re-educates tumor-associated macrophages to an antitumor phenotype. Molecular Biology of the Cell, 2015, 26, 3178-3189.	2.1	44
14	Dysregulated expression of miR-101b and miR-26b lead to age-associated increase in LPS-induced COX-2 expression in murine macrophage. Age, 2015, 37, 97.	3.0	16
15	<scp>TRAIL</scp> receptor deficiency sensitizes mice to dextran sodium sulphateâ€induced colitis and colitisâ€associated carcinogenesis. Immunology, 2014, 141, 211-221.	4.4	22
16	Human T-Cell Leukemia Virus Type 1 Tax-Deregulated Autophagy Pathway and c-FLIP Expression Contribute to Resistance against Death Receptor-Mediated Apoptosis. Journal of Virology, 2014, 88, 2786-2798.	3.4	30
17	TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis. Cancer Immunology, Immunotherapy, 2013, 62, 653-663.	4.2	25
18	<scp>TRAIL</scp> â€induced miRâ€146a expression suppresses <scp>CXCR</scp> 4â€mediated human breast cancer migration. FEBS Journal, 2013, 280, 3340-3353.	4.7	39

#	Article	IF	CITATIONS
19	2A Peptide-based, Lentivirus-mediated Anti-death Receptor 5 Chimeric Antibody Expression Prevents Tumor Growth in Nude Mice. Molecular Therapy, 2012, 20, 46-53.	8.2	20
20	PRMT5 suppresses DR4-mediated CCL20 release via NF-κB pathway. Science Bulletin, 2012, 57, 4351-4355.	1.7	3
21	A novel antiâ€DR5 chimeric antibody and epirubicin synergistically suppress tumor growth. IUBMB Life, 2012, 64, 757-765.	3.4	8
22	Epirubicin potentiates recombinant adenoâ€associated virus type 2/5–mediated TRAIL expression in fibroblastâ€like synoviocytes and augments the antiarthritic effects of rAAV2/5â€TRAIL. Arthritis and Rheumatism, 2012, 64, 1345-1354.	6.7	12
23	Dysregulated expression of miRâ€146a contributes to ageâ€related dysfunction of macrophages. Aging Cell, 2012, 11, 29-40.	6.7	95
24	Adeno-associated virus-mediated anti-DR5 chimeric antibody expression suppresses human tumor growth in nude mice. Cancer Letters, 2011, 302, 119-127.	7.2	11
25	Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer, 2011, 11, 54.	2.6	39
26	A highlight of recent advances in immunology. Science China Life Sciences, 2011, 54, 1151-1152.	4.9	0
27	HIV Infection Enhances TRAIL-Induced Cell Death in Macrophage by Down-Regulating Decoy Receptor Expression and Generation of Reactive Oxygen Species. PLoS ONE, 2011, 6, e18291.	2.5	46
28	Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer. Molecular Cancer Therapeutics, 2010, 9, 1007-1018.	4.1	20
29	Targeting a Novel N-terminal Epitope of Death Receptor 5 Triggers Tumor Cell Death*. Journal of Biological Chemistry, 2010, 285, 8953-8966.	3.4	6
30	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces chemotactic migration of monocytes via a death receptor 4-mediated RhoGTPase pathway. Molecular Immunology, 2010, 47, 2475-2484.	2.2	25
31	Comparative Proteome Analysis of Splenic Lymphocytes in Senescence-Accelerated Mice. Gerontology, 2009, 55, 559-569.	2.8	6
32	Death receptor 5â€recruited raft components contributes to the sensitivity of Jurkat leukemia cell lines to TRAILâ€induced cell death. IUBMB Life, 2009, 61, 261-267.	3.4	15
33	Tax1 enhances cancer cell proliferation via Ras–Raf–MEK–ERK signaling pathway. IUBMB Life, 2009, 61, 685-692.	3.4	22
34	The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat. Biomaterials, 2009, 30, 4014-4020.	11.4	113
35	Nucleic Acids in Protein Samples Interfere with Phosphopeptide Identification by Immobilized-Metal-Ion Affinity Chromatography and Mass Spectrometry. Molecular Biotechnology, 2009, 43, 59-66.	2.4	6
36	Dynamic urinary proteomic analysis reveals stable proteins to be potential biomarkers. Proteomics - Clinical Applications, 2009, 3, 370-382.	1.6	32

#	Article	IF	CITATIONS
37	Knockdown of câ€FLIP <sub>L</sub> enhanced AD5â€10 antiâ€death receptor 5 monoclonal antibodyâ€induced apoptosis in human lung cancer cells. Cancer Science, 2009, 100, 940-947.	3.9	9
38	TRAIL receptor mediates inflammatory cytokine release in an NF-κB-dependent manner. Cell Research, 2009, 19, 758-767.	12.0	46
39	An agonistic monoclonal antibody against DR5 induces ROS production, sustained JNK activation and Endo G release in Jurkat leukemia cells. Cell Research, 2009, 19, 984-995.	12.0	20
40	Tumour necrosis factorâ€related apoptosisâ€inducing ligand (TRAIL)â€induced chemokine release in both TRAILâ€resistant and TRAILâ€sensitive cells via nuclear factor kappa B. FEBS Journal, 2009, 276, 581-593.	4.7	40
41	An update on gene therapy in China. Current Opinion in Molecular Therapeutics, 2009, 11, 547-53.	2.8	29
42	Alpha 1â€ <b>a</b> ntichymotrypsin/SerpinA3 is a novel target of orphan nuclear receptor Nur77. FEBS Journal, 2008, 275, 1025-1038.	4.7	17
43	AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sciences, 2008, 82, 1154-1161.	4.3	41
44	Sp1 is involved in 8-chloro-adenosine-upregulated death receptor 5 expression in human hepatoma cells. Oncology Reports, 2008, 19, 177-85.	2.6	15
45	Formyl peptide receptor-like 1 mediated endogenous TRAIL gene expression with tumoricidal activity. Molecular Cancer Therapeutics, 2007, 6, 2618-2625.	4.1	13
46	Erbin-regulated Sensitivity of MCF-7 Breast Cancer Cells to TRAIL via ErbB2/AKT/NF-ÂB Pathway. Journal of Biochemistry, 2007, 143, 793-801.	1.7	14
47	Actinomycin D enhances TRAIL-induced caspase-dependent and -independent apoptosis in SH-SY5Y neuroblastoma cells. Neuroscience Research, 2007, 59, 40-46.	1.9	35
48	Antibody gene therapy: an attractive approach for the treatment of cancers and other chronic diseases. Cell Research, 2007, 17, 303-306.	12.0	9
49	Microwave-assisted Protein Preparation and Enzymatic Digestion in Proteomics. Molecular and Cellular Proteomics, 2006, 5, 769-776.	3.8	138
50	v-Fos transformation effector binds with CD2 cytoplasmic tail. Science Bulletin, 2006, 51, 38-47.	1.7	5
51	Expression of human soluble TRAIL in Chlamydomonas reinhardtii chloroplast. Science Bulletin, 2006, 51, 1703-1709.	1.7	40
52	An Integrated Machine Learning System to Computationally Screen Protein Databases for Protein Binding Peptide Ligands. Molecular and Cellular Proteomics, 2006, 5, 1224-1232.	3.8	17
53	Therapeutic Expression of an Anti-Death Receptor 5 Single-Chain Fixed-Variable Region Prevents Tumor Growth in Mice. Cancer Research, 2006, 66, 11946-11953.	0.9	23
54	Concanavalin A-captured Glycoproteins in Healthy Human Urine. Molecular and Cellular Proteomics, 2006, 5, 560-562.	3.8	109

#	Article	IF	CITATIONS
55	Comparative Proteome Analysis of Breast Cancer and Normal Breast. Molecular Biotechnology, 2005, 29, 233-244.	2.4	18
56	A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Medicine, 2005, 11, 875-879.	30.7	2,986
57	PKCδ protects human breast tumor MCF-7 cells against tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis. Journal of Cellular Biochemistry, 2005, 96, 522-532.	2.6	31
58	Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology, 2005, 42, 1355-1363.	7.3	39
59	Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. International Journal of Cancer, 2005, 116, 314-321.	5.1	38
60	Human urine proteome analysis by three separation approaches. Proteomics, 2005, 5, 4994-5001.	2.2	134
61	Overexpression of Soluble TRAIL Induces Apoptosis in Human Lung Adenocarcinoma and Inhibits Growth of Tumor Xenografts in Nude Mice. Cancer Research, 2005, 65, 1687-1692.	0.9	116
62	A Novel Anti-human DR5 Monoclonal Antibody with Tumoricidal Activity Induces Caspase-dependent and Caspase-independent Cell Death. Journal of Biological Chemistry, 2005, 280, 41940-41952.	3.4	71
63	AMASS: Software for Automatically Validating the Quality of MS/MS Spectrum from SEQUEST Results. Molecular and Cellular Proteomics, 2004, 3, 1194-1199.	3.8	33
64	A Systematical Analysis of Tryptic Peptide Identification with Reverse Phase Liquid Chromatography and Electrospray Ion Trap Mass Spectrometry. Genomics, Proteomics and Bioinformatics, 2004, 2, 174-183.	6.9	8
65	8-Chloro-adenosine sensitizes a human hepatoma cell line to TRAIL-induced apoptosis by caspase-dependent and -independent pathways. Oncology Reports, 2004, 12, 193-9.	2.6	6
66	Molecular Therapeutics of HBV. Current Gene Therapy, 2003, 3, 341-355.	2.0	16
67	TRAIL: A Potential Agent for Cancer Therapy. Current Molecular Medicine, 2003, 3, 727-736.	1.3	24
68	PI3K/Akt signaling pathway involved in regulation of T lymphocyte activation and apoptosis mediated by CD3ε. Science Bulletin, 2001, 46, 568-570.	1.7	2
69	Analysis of the ligand-binding domain of macrophage colony-stimulating receptor. Science Bulletin, 2000, 45, 1191-1195.	1.7	4
70	Cloning and identification of a novel binding protein of CD2 cytoplasmic domain. Science Bulletin, 2000, 45, 2263-2267.	1.7	1
71	Internalization and half-life of membrane-bound macrophage colony-stimulating factor. Science Bulletin, 2000, 45, 1697-1703.	1.7	12
72	Recombinant sTRAIL induces cell death of tumor cell lines as well as primary cancer cells. Science Bulletin, 1999, 44, 1306-1309.	1.7	3

#	Article	IF	CITATIONS
73	Z-ajoene induces tumor cells to die by apoptosis. Science Bulletin, 1998, 43, 1135-1140.	1.7	2
74	Modulating multidrug resistance through inhibiting of protein kinase C activity by phenothiazines. Science Bulletin, 1998, 43, 1196-1200.	1.7	2
75	Two tyrosines in CD3s-ITAM are required to induce T lymphocyte apoptosis. Science Bulletin, 1998, 43, 1480-1485.	1.7	1
76	Tyrosine Phosphorylation of the CD3-ε Subunit of the T Cell Antigen Receptor Mediates Enhanced Association with Phosphatidylinositol 3-Kinase in Jurkat T Cells. Journal of Biological Chemistry, 1997, 272, 25310-25318.	3.4	45
77	8-chloroadenosine induces apoptosis in human MOLT-4 cell line. Science Bulletin, 1997, 42, 592-597.	1.7	0
78	T lymphocyte apoptosis induced by CD8Î $\mu$ chimera. Science Bulletin, 1997, 42, 222-227.	1.7	2
79	Over-expression of CD3ε transgenes blocks T lymphocyte development. International Immunology, 1995, 7, 435-448.	4.0	51
80	Mitogenic Effect of Polyclonal Anti-Porcine Lymphocyte E-Receptor Antiserum IgG. Immunological Investigations, 1987, 16, 363-370.	2.0	0